Sphingosine-1-phosphate mediates a reciprocal signaling pathway between stellate cells and cancer cells that promotes pancreatic cancer growth

American Journal of Pathology

Volumn 184, Issue 10, 2014, Pages 2791-2802

  Bi, Yan ^a   Li, Jiachu ^a,b   Ji, Baoan ^a   Kang, Ningling ^a   Yang, Liu ^a   Simonetto, Douglas A ^a   Kwon, Jung H ^a   Kamath, Marielle ^a   Cao, Sheng ^a   Shah, Vijay ^a  

^a MAYO CLINIC   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; LYSOPHOSPHOLIPID; MMP9 PROTEIN, HUMAN; PHOSPHOTRANSFERASE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE KINASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER MODEL; CANCER SIZE; CELL ACTIVATION; CELL INFILTRATION; CELLS; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME SYNTHESIS; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; METASTASIS; MIGRATION; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL; PANCREATIC STELLATE CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; GENE EXPRESSION REGULATION; METABOLISM; PANCREAS; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYSOPHOSPHOLIPIDS; MATRIX METALLOPROTEINASE 9; PANCREAS; PANCREATIC NEOPLASMS; PANCREATIC STELLATE CELLS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 84922470562     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2014.06.023     Document Type: Article

References (54)

1. Kunkel GT, Maceyka M, Milstien S, Spiegel S: Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov 2013, 12:688-702.
2. Pyne NJ, Pyne S: Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010, 10:489-503.
3. Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, Delisle MB, Cuvillier O, Susini C, Bousquet C: Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther 2009, 8:809-820.
4. Ikeda H, Watanabe N, Ishii I, Shimosawa T, Kume Y, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Iitsuka S, Fujita R, Omata M, Chun J, Yatomi Y: Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1- phosphate receptor 2. J Lipid Res 2009, 50:556-564.
5. Sobel K, Menyhart K, Killer N, Renault B, Bauer Y, Studer R, Steiner B, Bolli MH, Nayler O, Gatfield J: Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smadindependent signaling. J Biol Chem 2013, 288:14839-14851.
6. Apte MV, Wilson JS, Lugea A, Pandol SJ: A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology 2013, 144:1210-1219.
7. Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, Friess H: The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol 2012, 9:454-467.
8. Omary MB, Lugea A, Lowe AW, Pandol SJ: The pancreatic stellate cell: A star on the rise in pancreatic diseases. J Clin Invest 2007, 117:50-59.
9. Pandol S, Gukovskaya A, Edderkaoui M, Dawson D, Eibl G, Lugea A: Epidemiology, risk factors, and the promotion of pancreatic cancer: role of the stellate cell. J Gastroenterol Hepatol 2012, 27(Suppl 2):127-134.
10. Vonlaufen A, Joshi S, Qu C, Phillips PA, Xu Z, Parker NR, Toi CS, Pirola RC, Wilson JS, Goldstein D, Apte MV: Pancreatic stellate cells: Partners in crime with pancreatic cancer cells. Cancer Res 2008, 68:2085-2093.
11. Mathison A, LieblA, Bharucha J, Mukhopadhyay D, Lomberk G, Shah V, Urrutia R: Pancreatic stellate cell models for transcriptional studies of desmoplasia-associated genes. Pancreatology 2010, 10:505-516.
12. Paulo JA, Urrutia R, Kadiyala V, Banks P, Conwell DL, Steen H: Cross-species analysis of nicotine-induced proteomic alterations in pancreatic cells. Proteomics 2013, 13:1499-1512.
13. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G: Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 1975, 15:741-747.
14. Chen WH, Horoszewicz JS, Leong SS, Shimano T, Penetrante R, Sanders WH, Berjian R, Douglass HO, Martin EW, Chu TM: Human pancreatic adenocarcinoma: In vitro and in vivo morphology of a new tumor line established from ascites. In Vitro 1982, 18:24-34.
15. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ: In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1999, 1:50-62.
16. Daniels C, Wilkes M, Edens M, Kottom T, Murphy S, Limper A, Leof E: Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004, 114:1308-1316.
17. Sato H, Seiki M: Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993, 8:395-405.
18. Gaiser S, Daniluk J, Liu Y, Tsou L, Chu J, Lee W, Longnecker DS, Logsdon CD, Ji B: Intracellular activation of trypsinogen in transgenic mice induces acute but not chronic pancreatitis. Gut 2011, 60:1379-1388.
19. Das A, Yaqoob U, Mehta D, Shah VH: FXR promotes endothelial cell motility through coordinated regulation of FAK and MMP-9. Arterioscler Thromb Vasc Biol 2009, 29:562-570.
20. Liu C, Billadeau DD, Abdelhakim H, Leof E, Kaibuchi K, Bernabeu C, Bloom GS, Yang L, Boardman L, Shah VH, Kang N: IQGAP1 suppresses TbetaRII-mediated myofibroblastic activation and metastatic growth in liver. J Clin Invest 2013, 123:1138-1156.
21. Galis ZS, Sukhova GK, Libby P: Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 1995, 9:974-980.
22. Li W, Yu CP, Xia JT, Zhang L, Weng GX, Zheng HQ, Kong QL, Hu LJ, Zeng MS, Zeng YX, Li M, Li J, Song LB: Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 2009, 15:1393-1399.
23. Johnson KR, Johnson KY, Crellin HG, Ogretmen B, Boylan AM, Harley RA, Obeid LM: Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J Histochem Cytochem 2005, 53:1159-1166.
24. Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J, Yuan J, Zheng YJ, Huang ZS, Li M: Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res 2008, 14:6996-7003.
25. Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Bielawski J, Hannun YA, Obeid LM: Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J 2009, 23:405-414.
26. Bayerl MG, Bruggeman RD, Conroy EJ, Hengst JA, King TS, Jimenez M, Claxton DF, Yun JK: Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk Lymphoma 2008, 49:948-954.
27. Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grosch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M: Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 2008, 112:41-52.
28. Huang WC, Nagahashi M, Terracina KP, Takabe K: Emerging role of sphingosine-1-phosphate in inflammation, cancer, and lymphangiogenesis. Biomolecules 2013, 3:408-434.
29. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2:737-744.
30. Coussens LM, Tinkle CL, Hanahan D, Werb Z: MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490.
31. Sultan A, Ling B, Zhang H, Ma B, Michel D, Alcorn J, Yang J: Synergistic effect between sphingosine-1-phosphate and chemotherapy drugs against human brain-metastasized breast cancer MDAMB- 361 cells. J Cancer 2013, 4:315-319.
32. Greuber EK, Smith-Pearson P, Wang J, Pendergast AM: Role of ABL family kinases in cancer: From leukaemia to solid tumours. Nat Rev Cancer 2013, 13:559-571.
33. Tanis KQ, Veach D, Duewel HS, Bornmann WG, Koleske AJ: Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Mol Cell Biol 2003, 23:3884-3896.
34. Colicelli J: ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal 2010, 3:re6.
35. Sato H, Kita M, Seiki M: v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements: A mechanism regulating gene expression independent of that by inflammatory cytokines. J Biol Chem 1993, 268:23460-23468.
36. Das A, Fernandez Zapico M, Cao S, Yao J, Fiorucci S, Hebbel R, Urrutia R, Shah V: Disruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration. J Biol Chem 2006, 281:39105-39113.
37. Schmidt RL, Park CH, Ahmed AU, Gundelach JH, Reed NR, Cheng S, Knudsen BE, Tang AH: Inhibition of RAS-mediated transformation and tumorigenesis by targeting the downstream E3 ubiquitin ligase seven in absentia homologue. Cancer Res 2007, 67:11798-11810.
38. Xu Z, Vonlaufen A, Phillips PA, Fiala-Beer E, Zhang X, Yang L, Biankin AV, Goldstein D, Pirola RC, Wilson JS, Apte MV: Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol 2010, 177:2585-2596.
39. Schneiderhan W, Diaz F, Fundel M, Zhou S, Siech M, Hasel C, Moller P, Gschwend JE, Seufferlein T, Gress T, Adler G, Bachem MG: Pancreatic stellate cells are an important source of MMP-2 in human pancreatic cancer and accelerate tumor progression in amurine xenograftmodel and CAM assay. J Cell Sci 2007, 120:512-519.
40. Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD: Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008, 68:918-926.
41. Ponnusamy S, Selvam SP, Mehrotra S, Kawamori T, Snider AJ, Obeid LM, Shao Y, Sabbadini R, Ogretmen B: Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol Med 2012, 4:761-775.
42. Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, Hait NC, Allegood JC, Price MM, Avni D, Takabe K, Kordula T, Milstien S, Spiegel S: Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitisassociated cancer. Cancer Cell 2013, 23:107-120.
43. Thamilselvan V, Li W, Sumpio BE, Basson MD: Sphingosine-1- phosphate stimulates human Caco-2 intestinal epithelial proliferation via p38 activation and activates ERK by an independent mechanism. In Vitro Cell Dev Biol Anim 2002, 38:246-253.
44. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 2002, 295:2387-2392.
45. Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006, 25:9-34.
46. Stetler-Stevenson WG: Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 1996, 148:1345-1350.
47. Overall CM, Kleifeld O: Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006, 6:227-239.
48. Zucker S, Cao J, Chen WT: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.Oncogene 2000, 19:6642-6650.
49. Sirvent A, Benistant C, Roche S: Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol Cell 2008, 100:617-631.
50. Hantschel O, Grebien F, Superti-Furga G: The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer Res 2012, 72:4890-4895.
51. Lo YH, Ho PC, Zhao H, Wang SC: Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016). Anticancer Res 2011, 31:789-795.
52. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G: Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002, 37:375-536.
53. Kawai H, Nie L, Yuan ZM: Inactivation of NF-kappaB-dependent cell survival, a novel mechanism for the proapoptotic function of c-Abl. Mol Cell Biol 2002, 22:6079-6088.
54. Moss RA, Moore D, Mulcahy MF, Nahum K, Saraiya B, Eddy S, Kleber M, Poplin EA: A multi-institutional phase 2 study of imatinib mesylate and gemcitabine for first-line treatment of advanced pancreatic cancer. Gastrointest Cancer Res 2012, 5:77-83.